Cited 3 times in
Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이정현 | - |
dc.contributor.author | 이호규 | - |
dc.date.accessioned | 2019-05-29T05:22:34Z | - |
dc.date.available | 2019-05-29T05:22:34Z | - |
dc.date.issued | 2019 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/169563 | - |
dc.description.abstract | AIM: To compare the risks of hospitalization for heart failure (HHF) associated with sulfonylurea (SU), dipeptidyl peptidase-4 inhibitor (DPP-4i), and thiazolidinedione (TZD) as add-on medications to metformin (MET) therapy using the data of Korean adults with type-2 diabetes from the Korean National Health Insurance database. METHODS: We identified 98,383 people who received SU (n = 42,683), DPP-4i (n = 50,310), or TZD (n = 5,390) added to initial treatment of MET monotherapy in patients with type-2 diabetes. The main outcome was the hospitalization for HHF. Hazard ratios for HHF by type of second-line glucose-lowering medication were estimated by Cox-proportional hazard models. Sex, age, duration of MET monotherapy, Charlson Comorbidity Index and additional comorbidities, and calendar year were controlled as potential confounders. RESULTS: The observed numbers (rate per 100,000 person-years) of HHF events were 1,129 (658) for MET+SU users, 710 (455) for MET+DPP-4i users, and 110 (570) for MET+TZD users. Compared to that for MET+SU users (reference group), the adjusted hazard ratios for HHF events were 0.76 (95% confidence interval 0.69-0.84) for MET+DPP-4i users and 0.96 (95% confidence interval 0.79-1.17) for MET+TZD users. CONCLUSION: DPP-4i as an add-on therapy to MET may lower the risks of HHF compared with SU. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Public Library of Science | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study | - |
dc.type | Article | - |
dc.contributor.college | Graduate School of Public Health (보건대학원) | - |
dc.contributor.department | Graduate School of Public Health (보건대학원) | - |
dc.contributor.googleauthor | Su Jin Lee | - |
dc.contributor.googleauthor | Kyoung Hwa Ha | - |
dc.contributor.googleauthor | Jung Hyun Lee | - |
dc.contributor.googleauthor | Hokyou Lee | - |
dc.contributor.googleauthor | Dae Jung Kim | - |
dc.contributor.googleauthor | Hyeon Chang Kim | - |
dc.identifier.doi | 10.1371/journal.pone.0211959 | - |
dc.contributor.localId | A04639 | - |
dc.relation.journalcode | J02540 | - |
dc.identifier.eissn | 1932-6203 | - |
dc.identifier.pmid | 30742667 | - |
dc.contributor.alternativeName | Lee, Jung Hyun | - |
dc.contributor.affiliatedAuthor | 이정현 | - |
dc.citation.volume | 14 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | e0211959 | - |
dc.identifier.bibliographicCitation | PLOS ONE, Vol.14(2) : e0211959, 2019 | - |
dc.identifier.rimsid | 62674 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.